Maxim Group set a $2.00 target price on IsoRay (NYSEAMERICAN:ISR) in a report published on Wednesday morning. The firm currently has a buy rating on the healthcare company’s stock.
Shares of IsoRay (NYSEAMERICAN:ISR) opened at $0.45 on Wednesday. IsoRay has a 52-week low of $0.38 and a 52-week high of $0.69. The company has a market capitalization of $25.35, a PE ratio of -4.09 and a beta of 1.11.
IsoRay (NYSEAMERICAN:ISR) last released its quarterly earnings results on Thursday, February 8th. The healthcare company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). IsoRay had a negative net margin of 95.25% and a negative return on equity of 69.11%. The company had revenue of $1.54 million during the quarter.
In other IsoRay news, VP Michael Krachon bought 55,000 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The shares were bought at an average price of $0.50 per share, for a total transaction of $27,500.00. Following the transaction, the vice president now directly owns 19,609 shares in the company, valued at $9,804.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink
. In the last 90 days, insiders have purchased 62,440 shares of company stock worth $31,092.
WARNING: “IsoRay (ISR) Given a $2.00 Price Target by Maxim Group Analysts” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.themarketsdaily.com/2018/02/15/isoray-isr-given-a-2-00-price-target-by-maxim-group-analysts.html.
IsoRay Company Profile
IsoRay, Inc is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds.
Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.